Significant events in the third quarter
- New positive interim data on treatment of patients with non-small cell lung cancer (NSCLC) in the CANFOUR study were presented at the ESMO conference; next steps were initiated for expansion of the clinical development of nadunolimab and platinum-based chemotherapy in non-squamous NSCLC.
- The CIRIFOUR study was fully recruited; next steps were also initiated for expansion in non-squamous NSCLC evaluating nadunolimab in combination with platinum-based chemotherapy and immunotherapy.
- Patient recruitment was completed for the extension cohort in pancreatic cancer in CANFOUR and nadunolimab was granted orphan drug status by the FDA for treatment of pancreatic cancer.
- The first patient was treated in CAPAFOUR, approval was obtained to start the CESTAFOUR study and an application to start the TRIFOUR study was submitted and approved by the Spanish authorities.
- Preclinical data were presented demonstrating the benefits of nadunolimab's mechanism of action over blockade of IL-1β alone.
-
The opposition against one of
Cantargia's European patents was rejected by theEuropean Patent Office .
Significant events after the end of the period
- Nadunolimab received a positive opinion from the EMA on orphan drug status for the treatment of pancreatic cancer.
- The first patient was treated in CESTAFOUR.
- Progress in the manufacturing process development for CAN10 was reported and start of the first clinical study for CAN10 was adjusted to Q3 2022.
Financial information
January -
- Net sales,
SEK 0 (0) million -
Operating loss,
SEK -264.5 (-117.5) million -
Loss after tax
SEK -262.3 (-116.6) million -
Loss per share, before and after dilution,
SEK -2.62 (-1.33) - Equity/assets ratio, 91 (93) per cent
-
Cash and cash equivalents,
SEK 335.9 (282.0) million -
Short-term investments,
SEK 312.0 (135.0) million
Third quarter 2021
- Net sales,
SEK 0 (0) -
Operating loss,
SEK -104.7 (-39.9) million -
Loss after tax,
SEK -103.8 (-39.6) million -
Loss per share, before and after dilution,
SEK -1.04 (-0.43)
In conjunction to the report,
The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q3-2021.
To attend through telephone, please dial-in at one of the numbers below:
SE: +46 8 50558368
The webcast will also be available on demand on
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This is information that
About
https://news.cision.com/cantargia-ab/r/cantargia-publishes-interim-report-for-third-quarter-2021,c3451109
https://mb.cision.com/Main/7470/3451109/1494237.pdf
https://mb.cision.com/Public/7470/3451109/a349992931dc4128.pdf
(c) 2021 Cision. All rights reserved., source